The board of directors at Acorda Therapeutics has docked the pay of CEO Ron Cohen for a series of missteps that hobbled the drug maker last year.

Cohen was due to receive a 2017 bonus of just under $255,000 — about half of his customary bonus — because Acorda only achieved 40 percent of its corporate goals for the year, according to a proxy statement filed Friday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • When the CEO of a company is not rewarded with a bonus, and is told that if the drug trials are deemed feasible for the use that patients will receive, and hopefully will be successful with the treatment protocol, then that is a significant justification for the pharmaceutical company to only reward the top executive any bonus, based on its efficacy. I hope that this is the way that all pharmaceutical companies reward the individuals who are employed by the companies, and/or removing them from their employment in the company.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy